HSP90AA1 and Miyoshi myopathy: Our group is now focusing on the potential of RAS-RAF-MEK-ERK pathway inhibitors, and we have already reported the synergistic combination effect of the novel selective heat shock protein (HSP)90α/β inhibitor, TAS-116, and RAS-RAF-MEK-ERK inhibitors in RAS-mutated or BRAF-mutated MM cells [29].